Jessica Hergert

Articles

CAR T-Cell Therapy Recipients May Require Specialized COVID-19 Vaccine Strategies

November 03, 2021

CAR T-cell therapies represent a potent treatment option for patients with heavily pretreated relapsed/refractory hematologic malignancies, however, the infection risk associated with treatment may hinder the efficacy of COVID-19 vaccines in this population.

New Clinical Trial Will Assess Novel ADC in Drug Resistant HER2+ Breast Cancer

October 23, 2021

The recently launched phase 2 ACE-Breast03 seeks to appraise the efficacy and safety of the novel antibody-drug conjugate, ARX788, in patients with metastatic HER2-positive breast cancer whose disease is resistant to previous targeted therapies.